An observational study in Urinary Bladder Neoplasms, sponsored by Janssen Korea, Ltd., Korea. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson — 2 open to participants now, 5 under way, 2 of them phase 3. Urinary Bladder Neoplasms · Johnson & Johnson.
Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 11th registered.
1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →2 of the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:
Janssen-Cilag Farmaceutica Ltda. · Sites in Portugal
Ages 18+
By country, each count listing its studies:
Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1 is below the median of 200 across 412 observational studies indexed under Urinary Bladder Neoplasms.
Median enrollment 71 across the 10 interventional studies, 126 across the 2 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Korea, Ltd., Korea, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
2 of the studies in Urinary Bladder Neoplasms by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT07735793Janssen Korea, Ltd., KoreaA Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea | 2026-11-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have received Bacillus Calmette-Guérin (BCG) therapy. HR-NMIBC is a type of bladder cancer in which cancer is confined to the inner lining of the bladder and has a high risk of returning or becoming more serious. BCG therapy is a treatment administered directly into the bladder to help prevent the cancer from returning or progressing.
The criteria were revised on the registry on Nov 9, 2026. See what changed
The study consists of participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who received Bacillus Calmette-Guérin (BCG) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who received intravesical Bacillus Calmette-Guérin (BCG) therapy following a qualifying transurethral resection of bladder tumor (TURBT) between September 1, 2015, and August 31, 2024, will be enrolled in the cohort. Data will be collected using the Health Insurance Review and Assessment Service (HIRA) claims database. No drug will be given as part of the study.
Percentage of Participants Receiving Bacillus Calmette-Guérin (BCG) Induction and Maintenance Therapy
Percentage of participants receiving BCG induction and maintenance therapy therapy will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Participants Reporting BCG Treatment Completion
The number of participants reporting completion of BCG treatment will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Time Between Successive BCG Instillations
The time between successive BCG instillations will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Intravesical Chemotherapy Instillations
The number of intravesical chemotherapy instillations after the index date will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Duration of Intravesical Chemotherapy
The duration of intravesical chemotherapy after the index date will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Frequency of Intravesical Chemotherapy Instillations
The frequency of intravesical chemotherapy instillations after the index date will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Time Between Successive Intravesical Chemotherapy Instillations
The time between successive intravesical chemotherapy instillations after the index date will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Participants Requiring BCG Re-treatment
The number of participants requiring BCG re-treatment following the index BCG course will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Participants Requiring Intravesical Chemotherapy
The number of participants requiring intravesical chemotherapy following the index BCG course will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Time to Next Treatment
Time to next treatment is defined as the time from the index date to the date of the next localized or systemic intervention for bladder cancer.
Time frame: At 6, 9, 12, and 24 months after the index date
Time to Cystectomy
Time to cystectomy is defined as the time from the index date to the date of radical cystectomy.
Time frame: From the index date to radical cystectomy, death, or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Radical Cystectomy Incidence
The cumulative incidence of radical cystectomy will be estimated, with death treated as a competing risk.
Time frame: At 12, 24, and 36 months after the index date
Metastasis-Free Survival
Metastasis-free survival is defined as the time from the index date to evidence of metastasis or death from any cause, whichever occurs first.
Time frame: At 6, 9, 12, and 24 months after the index date
Overall Survival
Overall survival is defined as the time from the index date to death from any cause.
Time frame: Up to 30 days, 90 days, 12 months and 3 years post-RC procedure
Number of Participants Requiring Repeat Transurethral Resection of Bladder Tumor (TURBT)
The number of participants requiring repeat transurethral resection of bladder tumor (TURBT) following the index BCG course will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Participants Requiring Systemic Therapy
The number of participants requiring systemic therapy following the index BCG course will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Number of Participants Requiring Radical Cystectomy
The number of participants requiring radical cystectomy following the index BCG course will be reported.
Time frame: From the index date to death or the data cutoff of August 31, 2025, whichever is earlier (up to 10 years)
Recurrence-Free Survival
Recurrence-free survival is defined as the time from the index date to the first claims-based recurrence or progression proxy event or death due to any cause, whichever occurs first.
Time frame: At 3, 6, 9, 12, and 24 months after the index date
Time to Recurrence
Time to recurrence is defined as the time from the index date to the first claims-based recurrence proxy event.
Time frame: At 6, 9, 12, and 24 months after the index date
Time to Progression
Time to progression is defined as the time from the index date to the first claims-based progression proxy event.
Time frame: At 6, 9, 12, and 24 months after the index date
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.jnj.com
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.